Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity

Aim: In renal cell carcinoma (RCC), tumor heterogeneity generated challenges to biomarker development and therapeutic management, often becoming responsible for primary and acquired drug resistance. This study aimed to assess the inter-tumoral, intra-tumoral, and intra-lesional heterogeneity of know...

Full description

Bibliographic Details
Published in:	Exploration of Targeted Anti-tumor Therapy
Main Authors:	Melissa Bersanelli, Letizia Gnetti, Francesco Paolo Pilato, Elena Varotti, Federico Quaini, Nicoletta Campanini, Elena Rapacchi, Roberta Camisa, Paolo Carbognani, Enrico Maria Silini, Michele Rusca, Francesco Leonardi, Umberto Maestroni, Mimma Rizzo, Matteo Brunelli, Sebastiano Buti, Luca Ampollini
Format:	Article
Language:	English
Published:	Open Exploration Publishing Inc. 2023-08-01
Subjects:	renal carcinoma biomarkers heterogeneity immunohistochemistry
Online Access:	https://www.explorationpub.com/Journals/etat/Article/1002165

Similar Items

Rivel (Aude). Grotte de la Catette
by: Florian Téreygeol
Published: (2008-12-01)

Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease
by: Markus Tiemann, et al.
Published: (2020-03-01)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
by: Giuseppe Luigi Banna, et al.
Published: (2020-07-01)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
by: Melissa Bersanelli, et al.
Published: (2023-01-01)

PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development
by: Laura Oggianu, et al.
Published: (2023-04-01)

The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis
by: Xiaomin Fu, et al.
Published: (2025-05-01)

Comprehensive immunophenotyping reveals distinct tumor microenvironment alterations in anti-PD-1 sensitive and resistant syngeneic mouse model
by: Hiroyuki Inoue, et al.
Published: (2025-03-01)

Longitudinal evolution of incidentally detected solitary pure ground-glass nodules on CT: relation to clinical metrics
by: Mario Silva, et al.
Published: (2015-09-01)

The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab
by: Giulia Claire Giudice, et al.
Published: (2025-01-01)

Vibrational Properties of Pd Nanocubes
by: Alberto Flor, et al.
Published: (2019-04-01)

PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response
by: Joanna Zurko, et al.
Published: (2021-04-01)

Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review
by: Francesco Autore, et al.
Published: (2018-06-01)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
by: Silvia Pesce, et al.
Published: (2019-06-01)

Gradient material Pd-PdHx
by: M. V. Goltsova, et al.
Published: (2018-10-01)

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
by: Joanna Bialek, et al.
Published: (2022-12-01)

Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1
by: Hongpei Tan, et al.
Published: (2023-07-01)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
by: Bersanelli M, et al.
Published: (2018-09-01)

Molecular dynamics insights into the redox effects on PD-1/PD-L1 and PD-1/PD-L2 interactions
by: Rasulbek Mashalov, et al.
Published: (2025-09-01)

Immunoistochemical expression of PD-1 and PD-L1 in bone marrow biopsies of patients with acute myeloid leukemia
by: Francesco Romano, et al.
Published: (2020-05-01)

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
by: Alessandro Parisi, et al.
Published: (2019-01-01)

Cardiac autonomic and cortisol stress responses to real operations in surgeons: relationship with individual psychobiological characteristics and experience
by: Luca Carnevali, et al.
Published: (2023-02-01)

Performance and Long-Term Stability of Pd/PSS and Pd/Al2O3 Membranes for Hydrogen Separation
by: Simona Liguori, et al.
Published: (2014-03-01)

نقش PD-1/ PD-L1 و Anti-PD-1/ PD-L1 در پیشرفت و سرکوب سرطان
by: نرگس عبدالهی, et al.
Published: (2023-11-01)

Long-Term Response to PD-1 and CTLA-4 Blockade in an SCLC Patient with Negative PD-L1 Expression on Biopsy: A Case Report
by: Marco Cefalì, et al.
Published: (2023-03-01)

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01)

Precision Dosing in Presence of Multiobjective Therapies by Integrating Reinforcement Learning and PK‐PD Models: Application to Givinostat Treatment of Polycythemia Vera
by: Alessandro De Carlo, et al.
Published: (2025-06-01)

The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the “inflamed tumor” to the “inflamed patient”
by: Melissa Bersanelli, et al.
Published: (2021-07-01)

PD-L1 Expression Fluctuates Concurrently with Cyclin D in Glioblastoma Cells
by: Martina Tufano, et al.
Published: (2021-09-01)

Immunophenotype-guided interpretable radiomics model for predicting neoadjuvant anti-PD-1 response in stage III–IV d-MMR/MSI-H colorectal cancer
by: Xuan Zhang, et al.
Published: (2025-08-01)

82 Spatial immunophenotyping of longitudinal metastatic melanoma specimens to identify biomarkers of response and resistance to combination anti-LAG-3 + anti-PD-1-based immunotherapies
by: Georgina V Long, et al.
Published: (2023-11-01)

Progress of research on PD-1/PD-L1 in leukemia
by: Huizhen Cao, et al.
Published: (2023-09-01)

Regulatory mechanisms of PD-1/PD-L1 in cancers
by: Xin Lin, et al.
Published: (2024-05-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
by: Giovanna Polcaro, et al.
Published: (2024-03-01)

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
by: Alessandro Russo, et al.
Published: (2020-10-01)

PD-L1 inhibitors in the pipeline: Promise and progress
by: Vito Vanella, et al.
Published: (2018-01-01)

Radical hemithorax radiotherapy induces an increase in circulating PD-1+ T lymphocytes and in the soluble levels of PD-L1 in malignant pleural mesothelioma patients: a possible synergy with PD-1/PD-L1 targeting treatment?
by: Alberto Revelant, et al.
Published: (2025-04-01)

Hydrogen Sulfide Inhibits TMPRSS2 in Human Airway Epithelial Cells: Implications for SARS-CoV-2 Infection
by: Giulia Pozzi, et al.
Published: (2021-09-01)

Recent Advancements in Pd-Based Membranes for Hydrogen Separation
by: Nadia Cerone, et al.
Published: (2024-08-01)

Gas sensing properties of MWCNT layers electrochemically decorated with Au and Pd nanoparticles
by: Elena Dilonardo, et al.
Published: (2017-03-01)